This document provides information about the composition, characteristics, indications, specifications, dosage, and adverse reactions of Epirubicin Hydrochloride for Injection (Rapid Dissolution) produced by Pfizer.
This document provides detailed instructions for the pharmaceutical product Epirubicin Hydrochloride for Injection (Rapid Dissolution), marketed under the brand name 法玛新 (Famxin). It outlines the drug's composition, physical characteristics, and approved indications for treating various cancers including malignant lymphoma, breast cancer, lung cancer, and others. The text also specifies the available dosage forms, which are 10mg and 50mg vials. This manual is written in Chinese.
| Molecular Formula | C27H29NO11·HCl |
|---|---|
| Molecular Weight | 579.98 |
| Dosage Form | For Injection (Rapid Dissolution) |
| Available Strengths | 10mg; 50mg |
It is used to treat malignant lymphoma, breast cancer, lung cancer, soft tissue sarcoma, esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, melanoma, colorectal cancer, ovarian cancer, multiple myeloma, and leukemia.
For superficial bladder cancer, 50mg is dissolved in 25 to 50mL of saline and instilled into the bladder once a week for 8 times.
When the total cumulative dose exceeds 900mg/m2, the risk of progressive congestive heart failure increases significantly.